Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lapatinib ditosylate works in treating patients with a
rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that
prostate cancer has come back after previous treatment. Lapatinib ditosylate may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth and may delay or
prevent the progression of prostate cancer.